ARx Opens New Pharmaceutical Manufacturing Facility
ARx, LLC, a subsidiary of Adhesives Research, is pleased to announce the official opening of its new state-of-the-art pharmaceutical manufacturing facility just eighteen months after breaking ground.
The new 25,000 square-foot facility is designed to manufacture dissolvable film, transdermal, and buccal drug delivery systems for over-the-counter (OTC), prescription, and biopharmaceutical products. The globally-compliant facility triples ARx's manufacturing capacity and laboratory space to support its rapidly growing portfolio of projects and clients.
ARx currently supports multiple commercial thin film products sold in the United States, Canada and Latin America, including Novartis Consumer Health's Triaminic Thin Strips pediatric and infant cough and cold products, Theraflu Thin Strips cold and flu products, and Gas-X Thin Strips anti-gas relief products. The current facility and evolving pipeline further supports ARx's market leadership by quadrupling potential strip output to over 1.4 billion strips per year.
"We have used our knowledge and twenty-plus years of experience in the pharmaceutical industry to build a modern, globally-compliant facility that allows us to streamline the manufacturing process and create an efficient and flexible process for our clients," said Beth Vondrak, ARx Vice President and General Manager.
Dissolvable thin film technology gives consumers a choice of delivery options for taking OTC and prescription medicines. The key benefits of the technology include quick and precise dosing, convenience and portability. These films have proven to be very popular for the pediatric population, who usually ingest the entire thin film dose (versus liquids that can be expelled from the mouth), as well as with geriatric patients and other individuals who have difficulty swallowing pills and those who prefer on-the-go relief.
ARx, a subsidiary of Adhesives Research, was created in 2005 to address the growing global need for innovative delivery of active drug-containing systems and is a custom developer and supplier of high-quality drug and biopharmaceutical delivery materials and technologies for the pharmaceutical industry. Adhesives Research has over 20 years of experience in providing unique components for transdermal, oral and topical drug delivery. The new facility brings the total square footage at the company's corporate headquarters to more than 240,000 square feet.
For more information on ARx and Adhesives Research, please call 717-235-7979 (1-800-445-6240) or visit www.adhesivesresearch.com.
Source: ARx, LLC